In an in vivo study, ipilimumab and tremelimumab (another anti-CTLA-4 mAb) mediated intratumoral Treg depletion and CD8+-to-Treg ratio augmentation and promoted tumor rejection.296. The gene discussed is CD8A; the disease is neoplasm.